Use search to browse all 100+ peptides
Bremelanotide, Vyleesi
A synthetic peptide analog of alpha-MSH used to treat hypoactive sexual desire disorder by activating melanocortin receptors to enhance sexual arousal.
Clayton. Anita H AH; Kingsberg. Sheryl A SA; Goldstein. Irwin I
The paper reviews how doctors can spot and treat low sexual desire in women. It says the only FDAâapproved drug right now is flibanserin, but a peptide called bremelanotide (also known as PTâ141) is in lateâstage trials and might become another option.
Croft. Harry A HA
The review explains that too much serotonin in the brain can dampen sexual desire in women, while dopamine and other chemicals boost it. Most drugs that help with low desire work by lowering serotonin or raising dopamine, and the only approved pill right now is flibanserin. The peptide bremelanotide (PTâ141) is mentioned as one of several agents that target these pathways, but the paper doesnât give new data on it.
Hellstrom. W J G WJ
The abstract explains that most current erectile dysfunction drugs work only on the penis, while a new peptide called bremelanotide (PT-141) works in the brain to boost sexual desire and response. Early studies suggest it could become the first drug that helps menâs sexual function by acting centrally, but more research is still needed.
Miller. Melanie K MK; Smith. Joshua R JR; Norman. Jacqueline J JJ; Clayton. Anita H AH
The paper reviews current and experimental drugs for female sexual dysfunction, including hormones, flibanserin, and the peptide bremelanotide (ptâ141). It highlights that many promising compounds stall because clinical trials lack clear success measures and because women's sexual health is still underâstudied. For DIY health enthusiasts, the main takeâaway is that bremelanotide shows promise but isnât yet approved, and that any selfâexperimentation should be cautious and based on limited data.
Pyke. Robert E RE; Clayton. Anita H AH
In studies of women with low sexual desire, both drug treatments (including the peptide bremelanotide, also called pt-141) and talkâtherapy approaches showed a very large improvement (Cohen's d ââŻ1.0). A sugarâpill placebo still helped a fair amount (dâŻââŻ0.55), while doing nothing (waitâlist) barely moved the needle (dâŻââŻ0.05).
Bardhan. Mainak M; Anand. Ayush A; Javed. Amaan A; Chilo. Maria Andrea MA; Khan. Nida N; Garg. Tulik...
Melanocortin receptors (MCRs) are proteins that affect everything from skin color and appetite to stress, immunity, and brain function. Different genetic variants of these receptors are linked to diseases like melanoma, obesity, diabetes, depression, and many inflammatory conditions. Several drugs that activate MCRsâincluding bremelanotide (ptâ141), afamelanotide, and setmelanotideâare already FDAâapproved for sexual desire, a rare skin disorder, and obesity, and early data suggest they might also help with inflammation.
Dhillon. Sohita S; Keam. Susan J SJ
Bremelanotide (Vyleesiâ˘) is a synthetic peptide that mimics a natural hormone and has been approved in the US to treat low sexual desire in premenopausal women. It works by activating a brain receptor linked to sexual response and is taken as a selfâinjected, onâdemand shot. The drug was developed by Palatin, licensed to AMAG, and passed Phase 3 trials before FDA approval.
Belkin. Zoe R ZR; Krapf. Jill M JM; Goldstein. Andrew T AT
This review looks at drugs that are still in early testing for women who have low sexual desire, a condition that currently has no approved medication. One of the candidates is ptâ141 (bremelanotide), a peptide that may boost desire when given as a nasal spray or injection. The paper lists several other compounds in Phase IâII trials, but all are experimental and not yet on the market.
Toledo. Rafaela Germano RG; Winkelman. William D WD; Reyes-Gonzalez. Daniela D; Bergeron. Sophie S;...
A big review looked at how to treat women who have trouble with sexual desire, arousal, or orgasm (but no pain). It found that a talkâtherapy called mindfulness CBT helps all three areas, a pill called flibanserin helps desire, and the peptide bremelanotide (ptâ141) helps desire and arousal. All three also lower sexual distress, but the studies didnât compare the therapies directly.
Pettigrew. Jessica A JA; Novick. Andrew M AM
Half of US women have sexual function issues, and low sexual desire (HSDD) is the most common. Doctors often miss it, but there are tools to diagnose it and two FDAâapproved drugsâflibanserin (a pill) and bremelanotide (ptâ141, a peptide injection). The review explains how hormones and brain chemicals affect desire and suggests how clinicians can assess and treat the condition.
Gelman. Faina F; Atrio. Jessica J
This paper reviews the only FDAâapproved drug for low sexual desire in preâmenopausal women, flibanserin, and notes its sideâeffects and that it isnât approved for postâmenopausal women. It also lists other drugsâincluding the peptide bremelanotide (ptâ141)âand nonâdrug approaches that might help, but says the evidence for most of them is weak or limited.
Sauter. Max M; Uhl. Philipp P; Burhenne. Jürgen J; Haefeli. Walter E WE
Researchers built a superâsensitive test to measure the peptide bremelanotide (ptâ141) in blood and used it to see if taking the drug by mouth works in dogs. The test works well, but the dogs barely absorbed the peptide when given orally, meaning itâs not effective that way.
Mestria. Serena S; Odoardi. Sara S; Frison. Giampietro G; Strano Rossi. Sabina S
The paper shows how a highâtech lab method (LCâHRMS) can spot the skinâpigment and sexualâenhancement peptides melanotanâŻII and bremelanotide (ptâ141) in seized blackâmarket products, confirming theyâre being sold illegally alongside steroids and other drugs.
Borland. Johnathan M JM; Kohut-Jackson. Abigail L AL; Peyla. Anna C AC; Hall. Megan Al MA; Mermelste...
In a study using female Syrian hamsters, the drug bremelanotide (Vyleesi) did not change the levels of certain brain receptors linked to reward or make sexual activity feel more rewarding. The drugâs effects on the brainâs pleasure circuit appear minimal in this animal model.
Both. Stephanie S
The review says that a few drugs, including the peptide bremelanotide (also called PT-141), are being tested to help women who have low sexual desire, but the benefits seen so far are modest and probably need to be combined with therapy.
Serilmez. Murat M; Abuelrub. Anwar A; Erol. Ismail I; Durdaği. Serdar S
A computerâbased study looked at existing FDAâapproved drugs and found that a few, including the peptide bremelanotide (also known as PTâ141), might stick to key COVIDâ19 proteins and block the virus in theory. The work is purely virtual and needs lab and clinical testing before any realâworld use.
Derogatis. Leonard R LR; Revicki. Dennis A DA; Rosen. Raymond C RC; Jordan. Robert R; Lucas. Johna J...
Researchers checked that a questionnaire (FSDS-DAO) used to measure women's sexual distress is reliable and works well in a study of the peptide bremelanotide (ptâ141). The tool proved consistent and sensitive to changes, meaning future trials can trust the results it captures.
Spielmans. Glen I GI; Ellefson. Elaine M EM
The study looked at how well the usual questionnaires measure the benefits of bremelanotide (pt-141) for women with low sexual desire. It found that many of the scores used arenât proven to be reliable for this condition, and the drug only showed tiny or no improvements on most of the outcomes.
Althof. Stanley S; Derogatis. Leonard R LR; Greenberg. Sally S; Clayton. Anita H AH; Jordan. Robert...
A Phase 2b study showed that a single 1.75âŻmg injection of bremelanotide (also called PTâ141) can improve sexual desire and satisfaction in preâmenopausal women with low sexual drive, with a safety profile similar to placebo.
Aughton. K L KL; Hamilton-Smith. K K; Gupta. J J; Morton. J S JS; Wayman. C P CP; Jackson. V M VM
In rabbit tissue tests, the peptide bremelanotide (pt-141) did not relax vaginal muscle or arteries, while other neuropeptides like VIP, PACAP, and alphaâMSH did. This suggests pt-141âs effects on female sexual arousal are probably not due to direct peripheral muscle relaxation.